2 Great Tech Stocks Added to UBS Quality Growth Portfolio
As we have reported at length lately, most of the top Wall Street firms that we cover are making some final year-end portfolio moves to try to help investors finish out what has been for the most part a disappointing year. With both the Dow Industrials and the S&P 500 down for the year, we will need a solid rally to get the indexes back to the low to middle single digits.
In a new UBS research report, the Quality Grow at a Reasonable Price (Q-GARP) team makes some significant changes to the portfolio, adding some higher beta names while removing a huge pharmaceutical winner. The portfolio is handily outperforming the S&P 500 on a year-to-date basis, and it is an outstanding basket for aggressive growth investors looking for value.
This top specialty pharmaceutical stock is removed from the portfolio after a spectacular run and a recent bid from U.S. pharmaceuticals giant Pfizer. Allergan PLC (NYSE: AGN) is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines, and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories. It also operates the world’s third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines.
UBS removed the stock basically due to the sale of the generics business to Teva Pharmaceutical and the gigantic bid from Pfizer. The company will remain on UBS’s most preferred health care list. However due to both of these factors, it falls outside of the quantitative goals for the portfolio.
The Thomson/First Call consensus price target for Allergan is $362.40. Shares closed trading on Monday at $298.71.